S
Sutro Biopharma, Inc. (STRO)
NGM – Real vaqt narxi. Valyuta: USD
40.91
+1.60 (4.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
40.91
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
40.91
+1.60 (4.07%)
Yopilishda: May 12, 2026, 4:00 PM EDT
40.91
0.00 (0.00%)
Bozordan keyin: May 12, 2026, 4:10 PM EDT
Sutro Biopharma, Inc. onkologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya o'zining proprietary integratsiyalashgan hujayrasiz oqsil sintezi platformasi XpressCF va saytga xos kon'yugatsiya platformasi XpressCF+ ga imkon beruvchi saytga xos va yangi formatdagi antitel-dorilangan kon'yugatlarini (ADC) ishlab chiqadi. Uning asosiy mahsulot nomzodiga STRO-004 kiradi, bu to'qima omiliga (TF) yo'naltirilgan ADC bo'lib, TF-ifoda etuvchi qattiq o'smalarni, shu jumladan, kichik hujayrali bo'lmagan o'pka rakini, bosh va bo'yinning yassi hujayrali karsinomasi, bachadon bo'yni rakini, kolorektal rakni, oshqozon osti bezi o't yo'llari adenokarsinomasi, bachadon rakini va siydik pufagi rakinini davolash uchun mo'ljallangan. Kompaniya, shuningdek, katta yoshdagi va katta yoshdagi hamda chaqaloqlar uchun invaziv pnevmokokk kasalligini davolash bo'yicha II/III fazali klinik sinovlarda bo'lgan VAX-24 va Vax-31 pnevmokokk kon'yugatlangan vaktsina nomzodlarini va triple negativ ko'krak bezi rakini, kichik hujayrali bo'lmagan o'pka rakini va tuxumdon rakini, shuningdek, gematologik kasalliklarni davolash uchun anti-retseptor tirozin kinaza-ga o'xshash etalgan retseptor 1 (ROR1) ga qarshi yo'naltirilgan ADC bo'lgan STRO-003ni ishlab chiqadi. Sutro Biopharma, Inc. Vaxcyte bilan yuqumli kasalliklarni davolash yoki oldini olish uchun vaktsina nomzodlarini ishlab chiqish va aniqlash bo'yicha hamkorlik va litsenziyalash shartnomalariga ega; Tasly Biopharmaceuticals Co., Ltd. bilan STRO-002 ni Buyuk Xitoyda ishlab chiqish va tijoratlashtirish bo'yicha; Ipsen bilan ROR1 ga yo'naltirilgan ADC bo'lgan STRO-003 ni ishlab chiqish va tijoratlashtirish bo'yicha; va Astellas Pharma Inc. bilan immunostimulyator ADC ishlab chiqish bo'yicha hamkorlik shartnomalariga ega. Kompaniya ilgari Fundamental Applied Biology, Inc. nomi bilan tanilgan. Sutro Biopharma, Inc. 2003 yilda tashkil etilgan va uning shtab-kvartirasi Janubiy San-Frantsiskoda, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
| Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
| Jonathan Fawcett DPHIL, MBBS | Vice President of Clinical Development |
| Mr. David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel |
| Mr. Devendra Luhar | Senior Vice President of Technical Operations |
| Mr. Gregory K. Chow BA, CPA, MBA | Chief Financial Officer |
| Ms. Jane Chung R.Ph. | CEO & Director |
| Ms. Kari E. Leetch | Senior VP and Head of People & Culture |
| Ms. Regina Cheng | Vice President & Controller |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-22 | DEFA14A | stro-20260414.htm |
| 2026-03-30 | CORRESP | filename1.htm |
| 2026-03-23 | S-8 | stro-20260323.htm |
| 2026-03-23 | S-3 | d115714ds3.htm |
| 2026-02-10 | 8-K | d52363d8k.htm |
| 2025-12-17 | 8-K | d40412d8k.htm |
| 2025-12-03 | 8-K | stro-20251201.htm |
| 2025-11-06 | 8-K | stro-20251106.htm |
| 2025-11-06 | 10-Q | stro-20250930.htm |
| 2025-09-29 | 8-K | stro-20250929.htm |